Neogenomics
New Data Shore Up Evidence for Paired Tumor Origin, Molecular Testing in Cancer of Unknown Primary
Premium
Biotheranostics' CancerType ID can predict tumor origins for the majority of CUP patients, with reflex biomarker testing finding those eligible for targeted treatment.
Researchers Highlight Progress in Head and Neck Cancer MRD at ASCO, but Results Remain Preliminary
Premium
Clinicians said that residual disease tests could be of great benefit to this population, but advancing technologies will still have to prove themselves.
NSCLC Patients Who Should Get First-Line EGFR Inhibitors Are on Immunotherapy Instead, Study Finds
Premium
An analysis suggesting that 40 percent of EGFR mutation-positive and PD-L1-expressing lung cancers aren't treated according to guidelines has experts asking for a more in-depth look at why not.
JP Morgan Healthcare Conference Day 1: Bristol Myers Squibb, Vertex, Sarepta, Novartis, and More
On the first day, companies developing precision medicines and tests discussed plans for diversifying their portfolios and gaining regulatory approval for new products.
Natera Wins Preliminary Injunction Against NeoGenomics Labs, Preventing Sale of MRD Assay in US
NeoGenomics may continue to offer the assay for existing patients and for clinical trials, research studies, and projects already in process.